Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from two trials of vagus nerve stimulation to treat heart failure, sponsored by Boston Scientific and Cyberonics, respectively, were not particularly positive for the future of this therapy. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
You may also be interested in...
Cardio3 BioSciences Ups R&D Efforts After CV Stem Cell Product Clears Safety Review
Belgian regenerative therapies company plans to enlarge its R&D and partnering efforts after a pre-planned interim review by a Data Safety Monitoring Board gave the Phase III study of lead product C-Cure a clean bill of health.
Cardio3 BioSciences Ups R&D Efforts After CV Stem Cell Product Clears Safety Review
Belgian regenerative therapies company plans to enlarge its R&D and partnering efforts after a pre-planned interim review by a Data Safety Monitoring Board gave the Phase III study of lead product C-Cure a clean bill of health.
European Approval For BioControl Medical’s Nerve Stimulation System For Treatment-Resistant Depression
BioControl Medical’s FitNeS vagus nerve stimulation system now has a second approved European indication: treatment-resistant depression. This follows the implantable neuromodulation system’s first CE mark for drug-resistant epilepsy in 2010.